Bio-Path Holdings, Inc. ã¯ãç±³åœã§èšåºããã³åèšåºæ®µéã®è
«çåŠã«éç¹ã眮ãã RNAi ããç²åå»è¬åéçºäŒç€ŸãšããŠäºæ¥ãå±éããŠããŸããå瀟ã¯ãDNA ãç Žå£ããå®ãããšãç®çãšããããªãã·ãªãæ žé
ž (DNA) ããã¯ããŒã³ä¿®é£Ÿã§ãã P-ãšããã·ã䜿çšããè¬ç©ééããã³ã¢ã³ãã»ã³ã¹æè¡ã§ãã DNAbilize ã«åºã¥ã補åãéçºããŠããŸããå瀟ã®äž»ååè£è¬ã¯ãæ¥æ§éªšé«æ§çœè¡ç
(AML) ããã³éªšé«ç°åœ¢æçåçŸ€ã®æ²»çè¬ãšããŠç¬¬ II çžèšåºè©Šéšäžã® prexigebersen ã§ããå瀟ã¯ãŸãã飿²»æ§/åçºæ§ãªã³ãè
«ããã³æ
¢æ§ãªã³ãæ§çœè¡ç
ã®æ²»çè¬ãšã㊠Liposomal Bcl-2ãèµèãããéå°çްèèºãããAML ã®æ²»çè¬ãšããŠåèšåºæ®µéã«ãã Liposomal STAT3ãããã³ããŸããŸãªåºåœ¢è
«ççšã® prexigebersen-A ãéçºããŠããŸãã Bio-Path Holdings, Inc. 㯠2007 幎ã«èšç«ããããããµã¹å·ãã¬ã¢ã«æ ç¹ã眮ããŠããŸãã